Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics announced the dosing of the first patient in the FOCUS-3 Phase 3 trial evaluating solriamfetol for adolescents with attention deficit hyperactivity disorder. The trial is a randomized, double-blind, placebo-controlled study designed to assess efficacy and safety in approximately 468 patients aged 12 to 17 over a 6-week treatment period.
Key figures
- Drug Name
- solriamfetol
- Phase Of Trial
- Phase 3
- Patients randomized
- approximately 468
- Trial duration weeks
- 6
- Us adult societal cost
- $120 billion
- Us child adhd prevalence
- 7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.